Novartis sold its vaccine business in 2015 to GlaxoSmithKline, one of many companies around the world now racing to make a drug. Some companies are already testing vaccine candidates on humans. "The results of the first clinical studies on the vaccine candidates should be available in autumn," Novartis CEO Vas Narasimhan told Frankfurter Allgemeine Zeitung (FAZ). Narasimhan, who headed development at Novartis's vaccine business before the Basel-based company concluded it was too small to keep and should be unloaded, said producing enough vaccine for the world would also be a challenge. "That's way too long," he told FAZ.

Source: bd News24 May 15, 2020 06:22 UTC